We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
226
PUT
Rocket Pharmaceuticals
RCKT
$343M
$474K 0.02%
+125
New +$3.93K
ADMS
227
DELISTED
Adamas Pharmaceuticals
ADMS
$463K 0.02%
28,200
-69,400
-71% -$1.05M
NVAX icon
228
CALL
Novavax
NVAX
$1.21B
$457K 0.02%
110
-40
-27% -$5.16K
CMRX
229
DELISTED
Chimerix, Inc.
CMRX
$443K 0.02%
+79,900
New +$366K
CBMXW
230
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$429K 0.02%
857,746
+2,575
+0.3% +$1.68K
AVXS
231
DELISTED
AveXis, Inc. Common Stock
AVXS
$412K 0.02%
+10,000
New +$380K
IOVA icon
232
CALL
Iovance Biotherapeutics
IOVA
$2.04B
$408K 0.02%
+496
New +$4.2K
NUROW
233
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$400K 0.02%
38,262
+10
+0% +$121
TXMD icon
234
PUT
TherapeuticsMD
TXMD
$23.8M
$399K 0.01%
+12
New +$4.38K
FLXN
235
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$395K 0.01%
+202
New +$3.42K
PRQR icon
236
ProQR Therapeutics
PRQR
$244M
$393K 0.01%
58,910
-51,090
-46% -$281K
CASC
237
DELISTED
Cascadian Therapeutics, Inc.
CASC
$392K 0.01%
39,817
-104,250
-72% -$739K
BNTC icon
238
Benitec Biopharma
BNTC
$414M
$385K 0.01%
1,077
-278
-21% -$115K
MDCO
239
PUT
DELISTED
Medicines Co
MDCO
$377K 0.01%
100
– –
ACOR
240
CALL
DELISTED
Acorda Therapeutics
ACOR
$374K 0.01%
+1
New +$2.98K
TMBR
241
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$363K 0.01%
44
-20
-31% -$211K
CYH icon
242
Community Health Systems
CYH
$382M
$359K 0.01%
+31,122
New +$359K
AMRN
243
PUT
Amarin Corp
AMRN
$297M
$358K 0.01%
56
– –
TPST icon
244
Tempest Therapeutics
TPST
$14.3M
$358K 0.01%
17
-29
-63% -$525K
KYNB
245
CALL
Kyntra Bio
KYNB
$27.4M
$339K 0.01%
+7
New +$3.3K
INCY icon
246
CALL
Incyte
INCY
$25.8B
$339K 0.01%
+36
New +$3.03K
NURO
247
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$338K 0.01%
343
+74
+28% +$74K
MNTA
248
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$321K 0.01%
275
-1,461
-84% -$17.2K
RIGL icon
249
Rigel Pharmaceuticals
RIGL
$723M
$319K 0.01%
8,690
-34,906
-80% -$1M
AVXL icon
250
PUT
Anavex Life Sciences
AVXL
$231M
$311K 0.01%
+858
New +$3.61K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.